RLYB
Rallybio Corporation
2.05
USD
This page is just a preview of the data found in TrendSpider’s full version
Rallybio Corporation stock is down -51.19% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 November’s closed higher than October. 100% of analysts rate it a buy.
Rallybio Corporation engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)
